肝功能障碍患者EVAR术后预后与APRI及MELD评分相关
基于NSQIP 2005-2016年非急诊EVAR数据,比较肝纤维化(APRI>0.5)与无纤维化患者的30天结局,发现纤维化患者死亡率和主要并发症显著升高,且MELD评分越高结局越差,提示可用于术前风险分层。
要点
- APRI>0.5定义的肝纤维化患者EVAR后30天死亡和主要并发症显著增加
- MELD评分升高与30天死亡率和主要并发症呈阶梯式增加
- MELD>10患者30天不良事件率超过5%,或需将EVAR尺寸阈值提高至>6cm
核心结论
- 肝纤维化显著增加EVAR术后30天死亡率和主要并发症。
- APRI和MELD评分可用于EVAR术前风险分层。
- MELD>10患者30天不良事件率超过5%,高于<6cm动脉瘤年破裂风险,或需将EVAR尺寸阈值提高至>6cm。
研究设计与样本
- 回顾性队列研究,使用NSQIP数据库纳入2005-2016年非急诊EVAR患者共18,484例。
- 其中肝纤维化(APRI>0.5)2,286例,无纤维化16,198例。
- 采用多变量回归校正基线因素差异。
主要发现
- 肝纤维化患者30天死亡率1.5% vs 2.4%(P<.01),主要并发症率显著更高。
- 多变量分析显示肝纤维化与30天死亡率(OR 1.5;95%CI 1.1-2.1)、重返手术室(OR 1.5;95%CI 1.2-1.8)、肺部并发症(OR 1.6;95%CI 1.2-2.0)、输血(OR 1.7;95%CI 1.5-2.0)及非家庭出院(OR 1.5;95%CI 1.3-1.8)独立相关。
- MELD<10、10-15、>15组30天死亡率分别为1.3%、2.3%、4.7%(P<.01),主要并发症率分别为7%、11%、15%(P<.01),校正后仍持续。
关键数值与推荐
- APRI>0.5用于识别显著肝纤维化。
- MELD评分分层:<10、10-15、>15。
- MELD>10患者30天不良事件率超过5%,高于<6cm动脉瘤年破裂风险。
临床怎么用
- EVAR术前应计算APRI和MELD评分以进行风险分层。
- 对肝纤维化患者,尤其MELD>10者,需充分评估手术风险并加强围术期管理。
- 肝纤维化患者或可考虑将EVAR尺寸阈值提高至>6cm。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liver cirrhosis dramatically increases morbidity and mortality after open surgical procedures and is often a contraindication to open repair of abdominal aortic aneurysms. However, limited data have evaluated the effect of liver disease on outcomes after endovascular repair of aortic aneurysms. METHODS: The National Surgical Quality Improvement Program was used to evaluate all nonemergent endovascular aneurysm repairs (EVARs) from 2005 to 2016. The aspartate transaminase to platelet ratio index is a sensitive, noninvasive screening tool used to screen for liver disease and was calculated for all patients. A value >0.5 was used to identify those with significant liver fibrosis. Demographics, comorbidities, and 30-day outcomes were then compared between patients with and patients without fibrosis. Additional analysis was then completed to assess the effect of increasing Model for End-Stage Liver Disease (MELD) score on 30-day outcomes. Multivariable regression was used to account for differences in baseline factors. RESULTS: EVAR was performed on 18,484 patients including 2286 with liver fibrosis and 16,198 without. Patients with liver fibrosis had an increased 30-day mortality (1.5% vs 2.4%; P < .01) and significantly higher rates of major morbidities including return to the operating room, pulmonary complications, transfusion, and discharge other than home. After multivariable analysis, patients with liver fibrosis had a significant increase in 30-day mortality (odds ratio [OR], 1.5; 95% confidence interval [CI], 1.1-2.1), return to the operating room (OR, 1.5; 95% CI, 1.2-1.8), pulmonary complications (OR, 1.6; 95% CI, 1.2-2.0), transfusion (OR, 1.7; 95% CI, 1.5-2.0), and discharge other than home (OR, 1.5; 95% CI, 1.3-1.8). In further analysis, mortality also increased in a stepwise fashion with increasing MELD score (MELD <10, 1.3%; MELD 10-15, 2.3%; MELD >15, 4.7%; P < .01), as did major complications (MELD <10, 7%; MELD 10-15, 11%; MELD >15, 15%; P < .01). These increases persisted in adjusted analysis. CONCLUSIONS: Liver fibrosis significantly increases mortality and major morbidity after EVAR. The aspartate transaminase to platelet ratio index and MELD score should be used for preoperative risk stratification. Moreover, current 30-day morbidity and mortality rates among patients with MELD scores >10 exceed 5%, which is higher than the annual rupture risk for aneurysms <6 cm. Therefore, an increased size threshold of >6 cm may be warranted before EVAR in patients with liver fibrosis.
引用
- Zettervall SL, Dansey K, Swerdlow NJ, et al. Aspartate transaminase to platelet ratio index and Model for End-Stage Liver Disease scores are associated with morbidity and mortality after endovascular aneurysm repair among patients with liver dysfunction. J Vasc Surg. 2020. PMID: 31964569. doi:10.1016/j.jvs.2019.10.101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。